Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Powerpoint - Blood Journal
Document related concepts
Transcript
Potent and specific antitumor effects of an anti-CD22– targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma by Dianne L. Newton, Hans J. Hansen, Stanislaw M. Mikulski, David M. Goldenberg, and Susanna M. Rybak Blood Volume 97(2):528-535 January 15, 2001 ©2001 by American Society of Hematology SDS-PAGE of LL2-onconase conjugate under reducing and nonreducing conditions.LL2onconase was prepared as described in “Materials and methods” and analyzed on a 4% to 20% polyacrylamide gel. Dianne L. Newton et al. Blood 2001;97:528-535 ©2001 by American Society of Hematology Binding of LL2-onconase conjugate to Daudi cells.Competitive binding analysis of LL2 or LL2onconase inhibition of binding of [125I]-labeled LL2 IgG2a antibody to human Daudi lymphoma cells expressing the CD22 antigen. Dianne L. Newton et al. Blood 2001;97:528-535 ©2001 by American Society of Hematology Cytotoxicity and specificity of LL2-onconase.(A) Cytotoxicity of conjugated (LL2-Onc) and unconjugated onconase (Onc) to Daudi (circle) or CA-46 (square) cells. Dianne L. Newton et al. Blood 2001;97:528-535 ©2001 by American Society of Hematology Monensin potentiates the cytotoxic activity of LL2-onconase.Daudi (A) or Ramos (B) cells were treated with increasing concentrations of LL2-onconase in the absence (solid squares) or presence (open squares) of monensin for 3 days before protein synthesis wa... Dianne L. Newton et al. Blood 2001;97:528-535 ©2001 by American Society of Hematology Cytotoxicity of LL2-onconase to cells increases with time.Daudi cells were treated for 1 hour (A) or continuously (B) with varying concentrations of LL2-onconase. Dianne L. Newton et al. Blood 2001;97:528-535 ©2001 by American Society of Hematology Treatment of minimal Daudi lymphoma disease with LL2-onconase or component proteins.Daudi lymphoma cells (5 × 106 cells) were injected ip, followed 1 day later for an additional 4 consecutive days with ip injections of PBS (open triangles), 80 μg LL2 (open ... Dianne L. Newton et al. Blood 2001;97:528-535 ©2001 by American Society of Hematology Treatment of aggressive minimal and advanced Daudi lymphoma disease with LL2-onconase or component proteins.Daudi lymphoma cells (5 × 106 cells) were injected iv, followed 1 or 7 days later with daily iv injections for 5 consecutive days of PBS (open triang... Dianne L. Newton et al. Blood 2001;97:528-535 ©2001 by American Society of Hematology
